Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Levodopa in parkinsonism

R Slome

    South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde
    |March 12, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Levodopa (L-dopa) initially provides significant benefit for Parkinsonism patients, with effects lasting up to five years. While response may decline, L-dopa appears to prolong life expectancy in these patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Diffuse arteritis, long-term immunosuppression and malignancy.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·1976
    Same author

    Sotalol in angina pectoris. A double-blind study.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·1976
    Same author

    In memoriam: Joseph Gardiner.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·1975
    Same author

    The use of intravenous verapamil in cardiac arrhythmias.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·1973
    Same author

    Withdrawal of propranolol and myocardial infarction.

    Lancet (London, England)·1973
    Same author

    The syndrome of recurrent idiopathic pericarditis.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·1968
    Same journal

    SAMA Health Summit Abstracts.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2026
    Same journal

    On behalf of the South African Medical Association (SAMA), The Scientific Committee of the SAMA Health Summit, is pleased to pesent this abstract issue, showcasing the posters and oral presentations delivered at the Summit, which was held from 22-24 May 2026.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2026
    Same journal

    Proceedings of the 2<sup>nd</sup> Data Driven Surgery Conference (DDSC 2025).

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2026
    Same journal

    Clinical practice guidelines for the management of fever and neutropenia in South African children and adolescents with cancer.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2026
    Same journal

    The changing fortunes of the District Health System in SA (1994 - 2020): A retrospective review.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2026
    Same journal

    Thomas Micheal Guntram Ignaz Rehle (1951 - 2025).

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2026
    See all related articles

    Area of Science:

    • Neurology
    • Pharmacology

    Background:

    • Parkinsonism is a debilitating neurological disorder.
    • Levodopa (L-dopa) is a primary treatment for Parkinsonism.

    Purpose of the Study:

    • To evaluate the long-term efficacy and effects of Levodopa (L-dopa) in Parkinsonism patients.
    • To review the impact of L-dopa on Parkinsonism symptomatology and survival.

    Main Methods:

    • Longitudinal study involving 20 patients with Parkinsonism.
    • Assessment of L-dopa response over a 5-year period.
    • Review of clinical effects and survival data.

    Main Results:

    • Maximal benefit from L-dopa observed at 3 years.
    • Continued considerable benefit noted after 5 years for initially responsive patients.

    Related Experiment Videos

  • Evidence suggests L-dopa may prolong life expectancy.

    • Conclusions:

    • L-dopa offers sustained therapeutic benefits in Parkinsonism, even after initial response decline.
    • The drug's impact on symptomatology is significant over the long term.
    • L-dopa treatment is associated with potentially increased life expectancy in Parkinsonism.